RARE Ultragenyx Pharmaceutical Inc
Price (delayed)
$37.31
Market cap
$3.45B
P/E Ratio
N/A
Dividend/share
N/A
EPS
-$6.29
Enterprise value
$3.32B
Ultragenyx is a biopharmaceutical company committed to bringing novel products to patients for the treatment of serious rare and ultra-rare genetic diseases. The company has built a diverse portfolio of
Highlights
The revenue rose by 29% year-on-year and by 7% since the previous quarter
RARE's EPS is up by 24% year-on-year
Ultragenyx Pharmaceutical's debt has increased by 18% from the previous quarter but it has decreased by 7% YoY
The equity has declined by 27% since the previous quarter and by 10% year-on-year
The quick ratio has decreased by 15% QoQ and by 8% YoY
Key stats
What are the main financial stats of RARE
Market
Valuations
Earnings
Shares outstanding
92.5M
Market cap
$3.45B
Enterprise value
$3.32B
Price to earnings (P/E)
N/A
Price to book (P/B)
13.88
Price to sales (P/S)
6.03
EV/EBIT
N/A
EV/EBITDA
N/A
EV/Sales
5.92
Revenue
$560.23M
Gross profit
$483.5M
Operating income
-$539.94M
Net income
-$569.18M
EBIT
-$567.59M
EBITDA
-$532.04M
Free cash flow
-$421.68M
Per share
Balance sheet
Liquidity
EPS
-$6.29
EPS diluted
-$6.29
Free cash flow per share
-$4.66
Book value per share
$2.69
Revenue per share
$6.19
TBVPS
$14.15
Total assets
$1.5B
Total liabilities
$1.24B
Debt
$40.34M
Equity
$248.3M
Working capital
$472.97M
Debt to equity
0.16
Current ratio
2.37
Quick ratio
2.13
Net debt/EBITDA
0.25
Margins
Efficiency
Dividend
EBITDA margin
-95%
Gross margin
86.3%
Net margin
-101.6%
Operating margin
-96.4%
Return on assets
-38.2%
Return on equity
-196.1%
Return on invested capital
-70.9%
Return on capital employed
-49%
Return on sales
-101.3%
Dividend yield
N/A
DPS
N/A
Payout ratio
N/A
RARE stock price
How has the Ultragenyx Pharmaceutical stock price performed over time
Intraday
3.9%
1 week
6.66%
1 month
-4.77%
1 year
-17.29%
YTD
-11.31%
QTD
3.04%
Financial performance
How have Ultragenyx Pharmaceutical's revenue and profit performed over time
Revenue
$560.23M
Gross profit
$483.5M
Operating income
-$539.94M
Net income
-$569.18M
Gross margin
86.3%
Net margin
-101.6%
The revenue rose by 29% year-on-year and by 7% since the previous quarter
Ultragenyx Pharmaceutical's net margin has increased by 27% YoY and by 5% from the previous quarter
The company's operating margin rose by 27% YoY and by 6% QoQ
The company's gross profit rose by 24% YoY and by 7% QoQ
Growth
What is Ultragenyx Pharmaceutical's growth rate over time
Valuation
What is Ultragenyx Pharmaceutical stock price valuation
P/E
N/A
P/B
13.88
P/S
6.03
EV/EBIT
N/A
EV/EBITDA
N/A
EV/Sales
5.92
RARE's EPS is up by 24% year-on-year
The equity has declined by 27% since the previous quarter and by 10% year-on-year
RARE's price to book (P/B) is 16% less than its last 4 quarters average of 16.5 and 4.3% less than its 5-year quarterly average of 14.5
The P/S is 57% lower than the 5-year quarterly average of 14.0 and 27% lower than the last 4 quarters average of 8.3
The revenue rose by 29% year-on-year and by 7% since the previous quarter
Efficiency
How efficient is Ultragenyx Pharmaceutical business performance
The ROE is up by 47% year-on-year but it is down by 4.2% since the previous quarter
RARE's return on sales is up by 28% year-on-year and by 6% since the previous quarter
The return on assets has increased by 15% year-on-year
The company's return on invested capital rose by 4.4% YoY but it fell by 2% QoQ
Dividends
What is RARE's dividend
DPS
N/A
Dividend yield
N/A
Payout ratio
N/A
There are no recent dividends present for RARE.
Financial health
How did Ultragenyx Pharmaceutical financials performed over time
The total assets is 21% more than the total liabilities
The current ratio is down by 16% QoQ and by 9% YoY
The quick ratio has decreased by 15% QoQ and by 8% YoY
Ultragenyx Pharmaceutical's debt is 84% less than its equity
Ultragenyx Pharmaceutical's debt to equity has soared by 60% from the previous quarter
The equity has declined by 27% since the previous quarter and by 10% year-on-year
All financial data is based on trailing twelve months (TTM) periods - updated quarterly, unless otherwise
specified. Data from 
and Sharadar.